<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01834664</url>
  </required_header>
  <id_info>
    <org_study_id>00109</org_study_id>
    <nct_id>NCT01834664</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Bone Marrow Derived Autologous Cells Treatment of Cerebral Palsy in Subjects Above 15 Years</brief_title>
  <acronym>BMACCP</acronym>
  <official_title>Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Cerebral Palsy in Subjects Above Years (BMACCP) .It is Self Funded (Patients' Own Funding) Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chaitanya Hospital, Pune</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chaitanya Hospital, Pune</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Study is Single arm, Single Centre trial to study the safety and efficacy of bone marrow
      derived autologous mononuclear cells (100 millions per dose)study enrollment duration 36
      months sample size 100 patients should be treated (above 15 years of age) with cerebral palsy
      in India. Primary outcome measures are improvement in walking ability and kinetic gait
      pattern.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cerebral Palsy is commonest cause of Disability in India and south East Asia. This Study is
      devised to quantify the safety and efficacy of bone marrow derived autologous mononuclear
      cells(100 millions per dose)study enrolment duration 36 months sample size 100 patients
      should be treated (above 15 years of age) with cerebral palsy, in India. Primary outcome
      measures are improvement in walking ability and kinetic gait pattern as per as various
      clinical scales and also changes in the brain.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in muscle rigidity using Ash worth scale</measure>
    <time_frame>6 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in dysregulated phospholipid Metabolism</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in walking ability and kinetic gait Pattern</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in overall motor control using oxford scale</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in orbitoFrontal-amygdala circuit and self-regulation of social -emotional behaviour</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in motor-linked implicit learning</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Ataxic Infantile Cerebral Palsy</condition>
  <arm_group>
    <arm_group_label>STEM CELL</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Transfer of autologous stem cell [MNCs ]intrathecally</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>stem cell (MNCs )</intervention_name>
    <description>Intra thecal transplantation of autologous stem cell [MNCs ]Per dose at the interval</description>
    <arm_group_label>STEM CELL</arm_group_label>
    <other_name>Intra thecal autologous stem cell MNCs</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject aged above 15 years with a diagnosis of Cerebral Palsy. Regional Nerve damage
             as shown by Magnetic Resonance Imaging(MRI)

          -  Patient suffer from cerebral palsy due to prenatal and postnatal cause,

          -  Willing to undergoing Bone Marrow derived autologous stem cell therapy.

          -  Able to Comprehend and give written informed consent form for the study

          -  willing to come to the hospital for follow up visits as per the protocol requirements

        Exclusion Criteria:

          -  History of meningitis,meningoencephalitis , epilepsy or life threatening allergic or
             immune -mediated reaction

          -  Hemodynamically unstable patients

          -  history of or concurrent autoimmune disease or acute episode if Guillain- barre
             syndrome

          -  peripheral Muscular dystrophy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ANANT E BAGUL, M.S</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHAITANYA HOSPITAL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sachin S Jamadar, Dortho</last_name>
    <phone>+918888788880</phone>
    <email>sac2751982@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chaitanya Hospital</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411009</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sachin S Jamadar, MBBS.DOrtho</last_name>
      <phone>8888788880</phone>
      <email>sac2751982@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Anant E Bagul, M.S.Ortho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2013</study_first_submitted>
  <study_first_submitted_qc>April 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2013</study_first_posted>
  <last_update_submitted>September 16, 2014</last_update_submitted>
  <last_update_submitted_qc>September 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chaitanya Hospital, Pune</investigator_affiliation>
    <investigator_full_name>Dr. Sachin Jamadar</investigator_full_name>
    <investigator_title>CO-Investigator</investigator_title>
  </responsible_party>
  <keyword>Ataxic Infantile Cerebral Palsy stem cell therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paralysis</mesh_term>
    <mesh_term>Cerebral Palsy</mesh_term>
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

